Company intelligence / Profile preview

Carnation Therapeutics Inc

Ownership: Private
Development stage: Preclinical

Overview

Developing antisense oligonucleotide-based therapies for cancer with a focus on lung cancer and melanoma. Currently raising funds to drive first cancer drug candidate to IND.

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotides
Industry: Biotech

Beyond the preview

Go deeper on Carnation Therapeutics Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carnation Therapeutics Inc.

Explore the full profile